Literature DB >> 29563157

Role of IGF-binding proteins in regulating IGF responses to changes in metabolism.

David R Clemmons1.   

Abstract

The IGF-binding protein family contains six members that share significant structural homology. Their principal function is to regulate the actions of IGF1 and IGF2. These proteins are present in plasma and extracellular fluids and regulate access of both IGF1 and II to the type I IGF receptor. Additionally, they have functions that are independent of their ability to bind IGFs. Each protein is regulated independently of IGF1 and IGF2, and this provides an important mechanism by which other hormones and physiologic variables can regulate IGF actions indirectly. Several members of the family are sensitive to changes in intermediary metabolism. Specifically the presence of obesity/insulin resistance can significantly alter the expression of these proteins. Similarly changes in nutrition or catabolism can alter their synthesis and degradation. Multiple hormones such as glucocorticoids, androgens, estrogen and insulin regulate IGFBP synthesis and bioavailability. In addition to their ability to regulate IGF access to receptors these proteins can bind to distinct cell surface proteins or proteins in extracellular matrix and several cellular functions are influenced by these interactions. IGFBPs can be transported intracellularly and interact with nuclear proteins to alter cellular physiology. In pathophysiologic states, there is significant dysregulation between the changes in IGFBP synthesis and bioavailability and changes in IGF1 and IGF2. These discordant changes can lead to marked alterations in IGF action. Although binding protein physiology and pathophysiology are complex, experimental results have provided an important avenue for understanding how IGF actions are regulated in a variety of physiologic and pathophysiologic conditions.
© 2018 Society for Endocrinology.

Entities:  

Keywords:  bone; cardiovascular; diabetes (all); growth factor receptors; growth factors

Mesh:

Substances:

Year:  2018        PMID: 29563157     DOI: 10.1530/JME-18-0016

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  31 in total

Review 1.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

2.  Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation.

Authors:  Masanobu Fujimoto; Melissa Andrew; Lihong Liao; Dongsheng Zhang; Gozde Yildirim; Patrick Sluss; Bhanu Kalra; Ajay Kumar; Shoshana Yakar; Vivian Hwa; Andrew Dauber
Journal:  Endocrinology       Date:  2019-06-01       Impact factor: 4.736

3.  World leaders describe the latest in IGF research.

Authors:  Emily Jane Gallagher; Derek LeRoith
Journal:  J Mol Endocrinol       Date:  2018-07       Impact factor: 5.098

Review 4.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 5.  Exercise and Diet: Uncovering Prospective Mediators of Skeletal Fragility in Bone and Marrow Adipose Tissue.

Authors:  Sarah E Little-Letsinger; Gabriel M Pagnotti; Cody McGrath; Maya Styner
Journal:  Curr Osteoporos Rep       Date:  2020-10-17       Impact factor: 5.096

6.  Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting.

Authors:  Calvin L Cole; John F Bachman; Jian Ye; Joseph Murphy; Scott A Gerber; Christopher A Beck; Brendan F Boyce; Gowrishankar Muthukrishnan; Joe V Chakkalakal; Edward M Schwarz; David Linehan
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-05-07       Impact factor: 12.910

Review 7.  Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain.

Authors:  William M Pardridge
Journal:  Front Med Technol       Date:  2020-11-16

8.  Anthropometric and biochemical correlates of PAPP-A2, free IGF-I, and IGFBP-3 in childhood.

Authors:  Masanobu Fujimoto; Jane C Khoury; Philip R Khoury; Bhanu Kalra; Ajay Kumar; Patrick Sluss; Claus Oxvig; Vivian Hwa; Andrew Dauber
Journal:  Eur J Endocrinol       Date:  2020-03       Impact factor: 6.664

9.  Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease.

Authors:  Takara L Stanley; Lindsay T Fourman; Isabel Zheng; Colin M McClure; Meghan N Feldpausch; Martin Torriani; Kathleen E Corey; Raymond T Chung; Hang Lee; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

Review 10.  Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin.

Authors:  Indira Purushothaman; Ian S Zagon; Joseph W Sassani; Patricia J McLaughlin
Journal:  Biochem Pharmacol       Date:  2021-07-26       Impact factor: 6.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.